iRhythm Technologies

iRhythm Technologies is an innovative company that has recently entered the Holter monitoring field. Headquartered in San Francisco, they have introduced a unique approach to continuous monitoring through their wearable ‘peel & stick’ patch called the Zio™ Patch. The Zio™ Patch is designed to be worn for an extended period of time, typically ranging from 7 to 14 days.

iRhythm Continuous ECG Monitoring Technology

iRhythm’s ZIO Patch has revolutionized ambulatory cardiac monitoring, offering distinct advantages over other monitoring options. Its superior compliance rate sets it apart from alternative cardiac monitoring methods. The design of the ZIO Patch has been well received by patients, making it their preferred choice compared to other monitoring modalities. iRhythm has achieved remarkable success in raising approximately $85 million in funding for the advancement of their continuous ECG monitoring technology with the Zio Patch.

Clinical Findings of ZIO® Patch

Various clinical trials conducted by iRhythm have provided compelling evidence that longer continuous monitoring is more effective in detecting different cardiac arrhythmias compared to the standard 24-hour monitoring period. For instance, a study carried out by iRhythm demonstrated that the ZIO Patch detected 57% more arrhythmias than a traditional 24-48 hour Holter monitor study.

Another study revealed that the ZIO Patch significantly outperforms an extended 48-hour Holter monitor in detecting arrhythmias. The ZIO Patch findings indicated:

• 51% of patients did not have their first symptom-triggered arrhythmia.
• 47% of patients experienced Atrial Fibrillation.
• 30% of patients experienced their first documented arrhythmia of any kind.
  

iRhythm is showcasing the superiority of their ZIO Patch in detecting asymptomatic Atrial Fibrillation (A Fib). The detection of A Fib is increasingly recognized as a crucial advancement in preventing and managing Transient Ischemic Attack (TIA) or stroke. Many experts believe that the ZIO Patch serves as a valuable tool for early detection of Atrial Fibrillation, especially in cases where this abnormal rhythm may go unnoticed with other forms of cardiac monitoring, such as Holter monitoring.

iRhythm Accreditations

As a Medicare-approved Independent Diagnostic Testing Facility (IDTF), iRhythm Technologies operates laboratories in both San Francisco, CA, and Linconshire, IL. The FDA granted approval to the iRhythm ZIO Patch in 2009, further validating its reliability and safety.